We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.95B
1-Year Est. Return 773.9%
This Fund
S&P 500
This Quarter Est. Return
+14.19%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$689M
AUM Growth
-$53.2M
Cap. Flow
-$90.8M
Cap. Flow %
-13.19%
Top 10 Hldgs %
41.31%
Holding
80
New
3
Increased
6
Reduced
50
Closed
5

Top Buys

Rank Stock Value
1
ANAB icon
AnaptysBio
ANAB
+$20.9M
2
JUNO
Juno Therapeutics, Inc.
JUNO
+$13.9M
3
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$9.22M
4
FWP
Forward Pharma A/S American Depositary Shares
FWP
+$6.73M
5
CHRS icon
Coherus Oncology
CHRS
+$2.49M

Top Sells

Rank Stock Value
1
NVRO
NEVRO CORP.
NVRO
+$22.7M
2
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$15.6M
3
ALDR
Alder Biopharmaceuticals
ALDR
+$10.7M
4
HRTX icon
Heron Therapeutics
HRTX
+$10.4M
5
BPMC
Blueprint Medicines
BPMC
+$8.66M

Sector Composition

Rank Sector Weight
1 Healthcare 99.92%
2 Miscellaneous 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MTVA
26
MetaVia Inc
MTVA
$10.3M
$10M 1.45%
14
– –
JNCE
27
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$9.56M 1.39%
+434,976
New +$9.22M
SYNH
28
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$9.17M 1.33%
200,000
– –
PTGX icon
29
Protagonist Therapeutics
PTGX
$9.28B
$8.76M 1.27%
683,600
-36,400
-5% -$587K
FLGT icon
30
Fulgent Genetics
FLGT
$600M
$8.19M 1.19%
750,000
-107,663
-13% -$1.27M
ARRY
31
DELISTED
Array Biopharma Inc
ARRY
$8.05M 1.17%
900,000
-250,000
-22% -$2.66M
BOLD
32
DELISTED
Audentes Therapeutics, Inc
BOLD
$7.24M 1.05%
424,660
-25,000
-6% -$404K
SRNE
33
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$6.68M 0.97%
1,690,800
-218,200
-11% -$1.09M
RIGL icon
34
Rigel Pharmaceuticals
RIGL
$844M
$6.62M 0.96%
200,000
-86,870
-30% -$2.21M
CFRX
35
DELISTED
ContraFect Corporation
CFRX
$6.39M 0.93%
4,438
-366
-8% -$574K
IVTY
36
DELISTED
Invuity, Inc
IVTY
$6.01M 0.87%
756,470
-10,996
-1% -$80.3K
DXCM icon
37
DexCom
DXCM
$33.3B
$5.93M 0.86%
280,000
-80,000
-22% -$1.56M
DERM
38
DELISTED
Dermira, Inc.
DERM
$5.8M 0.84%
170,000
-2,083
-1% -$67.2K
SGYP
39
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$5.59M 0.81%
1,200,000
-300,000
-20% -$1.74M
CRIS icon
40
Curis
CRIS
$2.74M
$5.56M 0.81%
1,000
-205
-17% -$1.14M
SCTL
41
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$5.16M 0.75%
657,850
-14,495
-2% -$101K
RARE icon
42
Ultragenyx Pharmaceutical
RARE
$1.28B
$5.08M 0.74%
75,000
-35,842
-32% -$2.73M
AGEN
43
Agenus
AGEN
$326M
$4.52M 0.66%
61,140
-11,260
-16% -$892K
INDP icon
44
Indaptus Therapeutics
INDP
$414M
$4.14M 0.6%
362
– –
AGRX
45
DELISTED
Agile Therapeutics
AGRX
$4.01M 0.58%
625
+343
+122% +$1.72M
CTMX icon
46
CytomX Therapeutics
CTMX
$604M
$3.97M 0.58%
230,000
-141,636
-38% -$1.86M
PFNX
47
DELISTED
Pfenex Inc.
PFNX
$3.34M 0.49%
574,966
-57,593
-9% -$433K
SNDX icon
48
Syndax Pharmaceuticals
SNDX
$1.58B
$3.3M 0.48%
240,403
– –
SGMO
49
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$3.12M 0.45%
600,000
-50,000
-8% -$201K
COLL icon
50
Collegium Pharmaceutical
COLL
$742M
$3.02M 0.44%
300,000
-155,515
-34% -$2.31M
1
2
3 4

Similar funds

AHC
Adell Harriman & Carpenter Houston, Texas $1.95B AUM 52.72% 1-Year Est. Return
FFS
Founders Financial Securities Towson, Maryland $1.95B AUM 22.17% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.95B AUM 25.88% 1-Year Est. Return
BFPW
BOK Financial Private Wealth Denver, Colorado $1.95B AUM 20.52% 1-Year Est. Return
MSA
MUFG Securities Americas New York $1.95B AUM 42.71% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Cormorant Asset Management's Q1 2017 Portfolio in Review

As of Q1 2017, Cormorant Asset Management held 80 positions worth $689M, down 7.2% from $742M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Cormorant Asset Management withdrew a net $90.8M in Q1 2017, closing 5 positions and reducing 50 holdings. Its most notable exit was Concert Pharmaceuticals, Inc., an estimated $5.54M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Cormorant Asset Management opened a new position in AnaptysBio worth $24.9M.

  • Cormorant Asset Management's largest Q1 2017 buy was AnaptysBio: 895,626 shares worth $24.9M.
  • Cormorant Asset Management added most to Forward Pharma A/S American Depositary Shares in Q1 2017, an estimated $6.73M increase.
  • Cormorant Asset Management's biggest Q1 2017 reduction was NEVRO CORP., cutting an estimated $22.7M.
  • Cormorant Asset Management fully exited Concert Pharmaceuticals, Inc. in Q1 2017, selling an estimated $5.54M.
  • Cormorant Asset Management's ten largest holdings make up 41% of its $689M portfolio in Q1 2017.
  • Cormorant Asset Management opened 3 new positions and closed 5 in Q1 2017.
  • Cormorant Asset Management's portfolio value fell 7.2% quarter-over-quarter to $689M.

Based on Cormorant Asset Management's 13F filing for Q1 2017, filed 15 May 2017.